The UK and US have established a significant commercial pact that will preserve zero import taxes on British medicine exports going into the US market.
Agreement Details of the Pact
As part of the deal, the UK has pledged to raise spending on drugs through the National Health Service (NHS). This commitment ensures that import taxes on these vital exports will remain at nothing for a duration of three years.
This development comes after earlier threats to dramatically increase tariffs on patented drug products, with increases floated as high as one hundred percent.
"This deal with the Britain bolsters the international landscape for new treatments and introduces much-needed equity to transatlantic drug exports," an announcement noted.
Economic Significance
Drugs constitute one of the Britain's largest goods shipped to the America, which is clearly the biggest buyer for leading British pharmaceutical firms.
Export figures reveal that in the year prior to the third quarter, the UK exported medicines valued at over eleven billion pounds to the US. This amount accounted for 17.4% of British export trade in that span.
"This guarantee safeguards jobs, increases capital expenditure and paves the way for the UK to become a global hub for biotech and pharma," a government official commented.
Specific NHS Changes
The pact entails several specific changes from the British government:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new therapies to be unaffordable by a quarter.
- Increased NHS Spending: There is a goal to double total NHS spending on medicines from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount drug companies must refund to the NHS to prevent overspending will be limited at 15%. Last year, refunds exceeded 20%.
Industry Background
This agreement comes amid a ongoing dispute between the drug companies and the UK government over medicine costs and approval rates.
The disagreement were heightened by claims that American consumers were charged significantly more for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been halted or scrapped, while substantial investments have been pledged toward American operations.
One official stated that the NHS must invest a greater share on drugs, noting that its expenditure on drugs had decreased as a percentage of its total funding over the last ten years.
